SCHEMBL12637293

SCHEMBL12637293

COc1cc2c(Oc3ccc(NC(=O)NC(=O)Cc4ccc(C)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 17/20 0.79
FLT3 P36888 4/20 0.77
KDR P35968 2/20 0.70
PLK4 O00444 1/20 0.70
STK25 O00506 1/20 0.70
CIT O14578 1/20 0.70
AURKA O14965 1/20 0.70
CHUK O15111 1/20 0.70
MUSK O15146 1/20 0.70
EPHB6 O15197 1/20 0.70
MAPK13 O15264 1/20 0.70
MAP3K13 O43283 1/20 0.70
DAPK3 O43293 1/20 0.70
MAP3K7 O43318 1/20 0.70
RIPK2 O43353 1/20 0.70
JAK2 O60674 1/20 0.70
ROCK2 O75116 1/20 0.70
PAK3 O75914 1/20 0.70
CDKL5 O76039 1/20 0.70
STK10 O94804 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882256 0.95 MET (0.79) METFLT3KDRPLK4STK25
SCHEMBL1877805 0.94 MET (0.79) METFLT3KDRPLK4STK25
SCHEMBL1879300 0.94 MET (0.73) METFLT3KDRPLK4STK25
SCHEMBL1882705 0.93 MET (0.76) METFLT3KDRPLK4STK25
SCHEMBL12637291 0.93 FLT3 (0.83) METFLT3KDRPLK4STK25
SCHEMBL1877942 0.92 MET (0.74) METFLT3KDRPLK4STK25
SCHEMBL12637279 0.91 FLT3 (0.75) METFLT3KDRPLK4STK25
SCHEMBL1876629 0.91 MET (0.74) METFLT3KDRPLK4STK25
SCHEMBL12637288 0.90 FLT3 (0.75) METFLT3KDRPLK4STK25
SCHEMBL12637277 0.90 FLT3 (0.75) METFLT3KDRPLK4STK25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324245-B2 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-12-04 US disclosed
US-8324245-B2 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-12-04 US disclosed
US-20110105747-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2011-05-05 US disclosed
US-20110105747-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105747-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME NR1H2, NR1H3, NR1H4 MET 306/4885FLT3 250/4885KDR 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.